Clearmind Medicine Inc. announced the enrollment of its first patients with Alcohol Use Disorder (AUD) in the ongoing clinical trial evaluating CMND-100, a proprietary psychedelic-based treatment candidate. The initial two patients were enrolled at Hadassah Medical Center in Jerusalem, Israel, marking the first administration of CMND-100 to AUD subjects. This milestone follows previous evaluations of CMND-100 at multiple doses in healthy participants and represents significant progress toward key clinical milestones for safety, tolerability, pharmacokinetics, and preliminary efficacy. Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company focused on developing non-hallucinogenic neuroplastogen-derived therapeutics for neuropsychiatric, metabolic, and addiction disorders.

Clearmind Medicine Inc. filed its unaudited condensed interim consolidated financial statements for the three and nine months ended July 31, 2026. The company reported a net loss of $907,291 for the quarter and $6,809,527 for the nine-month period, with cash and cash equivalents increasing to $12,035,210 from $3,923,058 at the prior year-end. The filing details significant capital raising activities, including the conversion of $8,899,559 in convertible promissory notes into 1,778,626 common shares and proceeds of $7,245,761 from equity issuances. Additionally, the company recorded a gain on the revaluation of derivative warrant liabilities of $496,061 for the nine months ended July 31, 2026. Clearmind Medicine Inc. operates in the biopharmaceutical industry and is engaged in clinical-stage development of psychedelic-derived neuroplastogens for neuropsychiatric disorders.

Clearmind Medicine Inc. announced that Yale University’s Institutional Review Board has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND-100, following positive safety results from Part A. The approval enables the company to accelerate enrollment at Yale School of Medicine’s Department of Psychiatry, joining other active sites including Johns Hopkins University and Israeli medical centers. Part A involved 24 participants across four ascending-dose cohorts who successfully completed treatment with no serious adverse events observed, reinforcing the compound's safety profile for treating Alcohol Use Disorder. Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company focused on developing non-hallucinogenic psychedelic-derived neuroplastogens for neuropsychiatric and addiction disorders.

On August 31, 2026, Clearmind Medicine Inc. entered into a definitive agreement to acquire a 51% controlling stake in Charging Robotics Ltd., an Israeli developer of wireless charging systems for automated parking and autonomous vehicles, for $2.5 million ($16,778 per share). The transaction is expected to close during the week of September 7, 2026, subject to customary conditions. As a condition to closing, Clearmind will provide Charging Robotics with a $1.5 million loan bearing 4.0% simple annual interest, due on the third anniversary unless extended based on cash flow performance. This strategic acquisition expands Clearmind's operations beyond its core business into the electric vehicle infrastructure sector.

On September 2, 2026, Clearmind Medicine Inc. entered into a conversion agreement with its CLA Investors to convert $687,500 in principal plus accrued interest totaling $696,079.50 from convertible promissory notes into common shares at an agreed price of $1.00 per share. The company also amended the floor price provision attached to its Securities Purchase Agreements to $1.00 per common share. Clearmind Medicine Inc. operates in the biotechnology industry, developing treatments for neurological and psychiatric disorders.

Clearmind Medicine Inc. announced the initiation of Phase IIa of its double-blind, placebo-controlled clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). The company has enrolled six patients to date: three at Tel Aviv Sourasky Medical Center and three at Hadassah Medical Center in Jerusalem. This marks the start of the first multiple-dose treatment phase of Part C, following the successful completion of the trial's initial safety part in healthy volunteers and a positive assessment by an independent Data and Safety Monitoring Board. Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for neuropsychiatric, metabolic, and addiction disorders.